CJC-1295 is a synthetic peptide hormone that can promote growth hormone secretion in a pulsatile manner, without causing the negative effects on appetite, cortisol, acetylcholine, prolactin, and aldosterone commonly observed with other peptides.
By binding to the growth hormone-releasing hormone receptor, CJC-1295 can effectively stimulate the production of growth hormone, leading to benefits in bone health, muscle development, insulin resistance, and lean body mass.
As a synthetic analog of somatocrinin, CJC-1295 has high selectivity and has been suggested to have anti-aging effects by promoting cellular repair and regeneration processes. Studies on mice have shown that treatment with CJC-1295 every 48-72 hours can lead to higher body weight and length compared to placebo-treated mice. In addition, CJC-1295 has been associated with beneficial effects on immune function and cognitive performance.
Combining CJC-1295 with Ipamorelin, another peptide that influences the growth hormone axis through a different pathway, may lead to even greater benefits without increasing the risk of side effects. Overall, CJC-1295 is a promising peptide with selective and potent growth hormone-releasing properties.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
CJC-1295 (without DAC) is a synthetic growth hormone–releasing hormone (GHRH) analog used in controlled laboratory research investigating pituitary signaling, pulsatile growth hormone dynamics, and downstream IGF-1 related pathways in preclinical models. The “without DAC” format refers to the absence of Drug Affinity Complex (DAC) modification, which is typically associated with extended half-life constructs in peptide design.
In research settings, CJC-1295 (without DAC) is commonly utilized as a signaling probe to explore how GHRH analogs influence GH release patterns, receptor binding dynamics, and endocrine feedback loops. Each vial is synthesized to research-grade standards and supported by third-party analytical testing to help labs maintain repeatable, protocol-driven experimentation.
CJC-1295 (without DAC) Research Peptide Specifications:
| Unit Size | 5 mg/vial |
| Unit Quantity | 1 vial |
| Purity (HPLC) | > 99% |
| Peptide Class | GHRH analog (research use) |
| Appearance | Lyophilized White Powder |
| Source | Chemical Synthesis |
| Storage Conditions | Store lyophilized CJC-1295 (without DAC) at −20 °C or below, protected from light and moisture. Reconstituted solutions should be stored at 2–8 °C and used promptly, in alignment with institutional standards. |
| Research Use Only | This peptide is supplied exclusively for laboratory research use. Not for human consumption, clinical use, or veterinary applications. |
CJC-1295 (without DAC) is designed to mimic and extend the activity of endogenous GHRH signaling at the pituitary receptor level, supporting research into growth hormone release patterns and endocrine cascade behavior. Unlike DAC-modified variants, the “no DAC” form is typically discussed in terms of shorter persistence and a stronger emphasis on pulsatile signaling models.
In preclinical research design, this matters because GH biology is heavily pattern-dependent. Many experimental frameworks distinguish between continuous exposure and pulsatile dynamics when evaluating downstream effects, including IGF-1 related markers, metabolic signaling readouts, and tissue-level transcriptional responses.
Because GH and IGF-related pathways overlap with other performance and recovery research categories, labs often map CJC-1295 (without DAC) alongside adjacent tool compounds when building broader study programs. Examples include pairing concepts with Ipamorelin (a GH secretagogue used in separate pathway studies), referencing repair-aligned peptides like BPC 157, or benchmarking tissue-quality endpoints with Thymosin Beta 4 in separate experiments.
Important Research Notice: Nordsci peptides are supported by independent third-party analytical testing to validate identity and purity via HPLC and mass spectrometry. A Certificate of Analysis (COA) is available for each lot to support documentation, QC review, and internal audit requirements.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE OR CONDITION.
CJC-1295 (without DAC) is frequently incorporated into research designs investigating pituitary receptor signaling and growth hormone pulse behavior. In these models, researchers may measure GH release patterns, receptor binding responses, and time-dependent hormone kinetics to evaluate how short-acting GHRH analogs influence endocrine output.
Because GH pulses can interact with downstream tissue signaling, these experiments often include secondary readouts such as transcriptional markers in muscle, liver, and adipose tissues, depending on the study objective and model type.
In GH/IGF axis research, investigators often examine how upstream stimulation influences downstream biomarkers tied to growth signaling and endocrine regulation. These studies may include IGF-related markers, binding proteins, and time-sequenced sampling designs to capture feedback effects across the hypothalamic–pituitary axis.
Where relevant, some labs reference growth-pathway comparators such as IGF1-LR3 as a separate tool compound for downstream signaling exploration, while keeping study variables separated to avoid confounding inputs.
If your lab is mapping GH pulse behavior, endocrine feedback loops, or IGF-related endpoints, standardizing sourcing and documentation can materially improve repeatability across cohorts.
Shop all peptidesBeyond core endocrine mapping, CJC-1295 (without DAC) is sometimes integrated into broader metabolic research programs where investigators track energy balance markers, substrate utilization, and body composition endpoints in controlled animal models. These experiments typically treat CJC-1295 (without DAC) as an upstream signal-modulator rather than a direct “outcome driver,” focusing on mechanistic interpretation.
For labs running parallel metabolic programs, peptides such as AOD-9604 or Frag 176-191 are often discussed as separate-category tools for adipose-focused endpoints, again emphasizing variable separation and endpoint clarity.
In some research frameworks, CJC-1295 (without DAC) is evaluated as part of a structured “stack” design where investigators test multiple compounds across staged phases to determine whether endocrine stimulation interacts with recovery, tissue integrity, or cognitive stress markers.
High-integrity stack work usually follows a phased approach: baseline characterization, single-compound arms, then multi-compound arms. This sequencing reduces interpretive noise and supports clearer causal inference across datasets.
Reconstitution Guidelines for Laboratory Use:
For laboratory work, each 5 mg vial of CJC-1295 (without DAC) is commonly reconstituted with bacteriostatic water or another appropriate sterile diluent to achieve the desired stock concentration. Concentration targets, administration route, and exposure schedules should be determined by the research team based on study design, assay requirements, and institutional approvals.
Protocol Design Considerations: Published research varies significantly by model type and endpoint selection. Labs should anchor protocol design to peer-reviewed literature, internal SOPs, and ethics/IACUC approvals. All peptide handling, storage, and disposal should follow institutional policy.
Note: The information above is provided as a high-level research reference only. All experimental use must be conducted by qualified personnel in appropriately equipped facilities, following applicable regulations and institutional policies.
Each lot of CJC-1295 (without DAC) is supported by a Certificate of Analysis documenting identity and purity. COA documentation can be used for protocol files, internal QC checklists, and procurement recordkeeping.
For institutional research use, CJC-1295 (without DAC) sourcing should prioritize analytical transparency, consistent labeling, and stable supply. Nordsci Peptides provides high-purity, research-grade peptides with lot-level documentation to support repeatable study execution across phases.
IMPORTANT: CJC-1295 (without DAC) is sold exclusively for in vitro and preclinical research applications. Not approved for human use or any therapeutic purpose. Researchers are responsible for complying with all applicable regulations and institutional policies governing peptide research.
Upgrade your procurement workflow with research-grade peptides backed by third-party testing and COAs. Keep your protocols clean, your documentation tight, and your studies repeatable.
Shop all peptides
